A Study of RAY1225 in Participants With Impaired Liver Function

Phase 1

Recruiting

• Conditions: Hepatic Impairment
• Interventions: Drug: RAY1225

• Registration Number: NCT06577415
• Lead Sponsor: Guangdong Raynovent Biotech Co., Ltd

Brief Summary

The purpose of this study is to assess how fast RAY1225 gets into the blood stream and how long it takes the body to remove it in participants with impaired liver function compared to healthy participants.

Detailed Description

Not available

Study Timeline

• Status Verified: 2024-08
• Study Start: 2024-08-26
• Study First Submitted: 2024-08-27
• Study First Submitted QC: 2024-08-27
• Study First Posted: 2024-08-29
• Last Update Submitted: 2025-03-18
• Last Update Posted: 2025-03-19
• Primary Completion: 2025-10-31
• Study Completion: 2025-11-15

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

1. Participant must be ≥ 18 to ≤ 75 years;

2. BMI ≥ 20 kg/m2 up to ≤ 32 kg/m2;

3. Participants (including partners) must use reliable methods of contraception during the study and until 6 months following the last dose of investigational product;

4. Signature of a dated Informed Consent Form (ICF) indicating that the participates has been informed of all the relevant aspects(including adverse events) of the trial prior to enrollment;

5. eGFR ≥ 60 mL/min/1.73 m2;

   Participants with Normal Hepatic Function Only:

6. Healthy males or females as determined by medical history, physical examination, and other screening procedures, with normal liver function;

   Participants with hepatic impairment only:

7. Males or females with chronic mild and moderate liver impairment, assessed by Child-Pugh scoring.

Exclusion Criteria

1. Participants with an allergic disposition (multiple drug and food allergies) or who, as determined by the investigator, are likely to be allergic to the investigational drug product or any component of the investigational drug product;

2. QTcF> 450ms;

3. Participants with serious infections, trauma, gastrointestinal surgery or other major surgical procedures within 4 weeks;

4. Participates who donated blood or bleeding profusely (> 400 mL) in the 3 months;

5. Pregnant or lactating women, or women of childbearing age with a positive pregnancy test;

6. Smoking averaged more than 10 cigarettes per day in the 3 months prior to screening;

7. Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia syndrome type 2;

   Participants with Normal Hepatic Function Only:

8. Any history of hepatic impairment, or potential presence of liver function impairment by physical examination and laboratory examination at screening.

   Participants with Hepatic Impairment Only:

9. Any history of clinically serious illness or disease or condition except for primary liver disease that the investigator believes may affect the results of the trial, including but not limited to a history of circulatory, endocrine, nervous, digestive, urinary, respiratory or hematological, immune, psychiatric, and metabolic disorders.

10. Participants with drug-induced liver injury; history of liver transplantation; cirrhosis in combination with the following complications: including but not limited to liver failure, hepatic encephalopathy, hepatocellular carcinoma, esophageal bleeding from ruptured fundic varices.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Moderate Hepatic Impairment	RAY1225	Participants with moderate hepatic impairment received single subcutaneous dose of 3 mg RAY1225.
Normal Hepatic Function	RAY1225	Participants with normal hepatic function received single subcutaneous dose of 3 mg RAY1225.
Mild Hepatic Impairment	RAY1225	Participants with mild hepatic impairment received single subcutaneous dose of 3 milligrams (mg) RAY1225.

Primary Outcome Measures

Name	Time	Method
Pharmacokinetics (PK): Area Under The Drug Concentration-Time Curve From Zero To Infinity (AUC[0-∞]) of RAY1225	DAY1~43	Pharmacokinetics (PK): Area Under The Drug Concentration-Time Curve From Zero To Infinity (AUC\[0-∞\]) of RAY1225.
PK: Maximum Observed Drug Concentration (Cmax) of RAY1225	DAY1~43	PK: Maximum Observed Drug Concentration (Cmax) of RAY1225

Secondary Outcome Measures

Name	Time	Method
Number of participants with drug-related adverse events as assessed by CTCAE v5.0	DAY1~43

Trial Locations

Locations (1)

Nanfang Hospital,South Medical Hospital; 🇨🇳 Guangzhou, Guangdong, China